Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury
Genro Fujisawa1, Koji Okada, Shigeaki Muto
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, 329-0498 Japan. genrfjs@attglobal.net
Abstract:
Long-term exposure of uninephrectomized rats to desoxycorticosterone acetate (DOCA)/salt induces cardiac fibrosis and hypertrophy through mineralocorticoid receptors (MRs). However, the underlying cellular mechanisms remain unclear. To determine whether Na/H exchange isoform 1 (NHE1) is involved in the cellular mechanisms, we examined the effects of a specific NHE1 inhibitor, cariporide, and an MR antagonist, spironolactone, on DOCA/salt-induced cardiac fibrosis and hypertrophy. Uninephrectomized rats were given 20 mg of DOCA (single subcutaneous injection) plus 0.9% NaCl/0.3% KCl to drink and were killed at 8 days. Two groups of rats given DOCA/salt were treated with either spironolactone (50 mg/kg per day SC) or cariporide (30 mg/kg per day PO) for 8 days. Control rats were treated with only high salt after the operation. The DOCA/salt-induced perivascular collagen deposition was completely abolished by cariporide and spironolactone. DOCA/salt-induced interstitial collagen deposition was partially and completely suppressed by spironolactone and cariporide, respectively. The rats exposed to DOCA/salt had cardiocyte hypertrophy in the subendocardial and subepicardial regions, a finding that was completely inhibited by cariporide but not by spironolactone. In rats given DOCA/salt, NHE1 protein expression was markedly increased. This was partially and completely reversed by spironolactone and cariporide, respectively. We concluded that cardiac NHE1 contributes to DOCA/salt-induced cardiac fibrosis and hypertrophy and that the NHE1 inhibitor cariporide completely prevents the detrimental effects of DOCA/salt on the heart. We also demonstrated that DOCA/salt-induced cardiac injury through the MRs partly occurs through NHE1 activation.
Insights
The study shows that inhibiting Na/H exchange isoform 1 (NHE1) with cariporide prevents desoxycorticosterone acetate (DOCA)/salt-induced heart damage. This highlights NHE1
Area of Science:
- Cardiovascular Research
- Cellular Mechanisms
- Pharmacology
Background:
- Long-term desoxycorticosterone acetate (DOCA)/salt exposure causes cardiac fibrosis and hypertrophy via mineralocorticoid receptors (MRs).
- The specific cellular pathways mediating these effects are not fully understood.
Purpose of the Study:
- To investigate the role of Na/H exchange isoform 1 (NHE1) in DOCA/salt-induced cardiac damage.
- To evaluate the efficacy of the NHE1 inhibitor cariporide and the MR antagonist spironolactone in preventing these changes.
Main Methods:
- Uninephrectomized rats received DOCA/salt treatment for 8 days.
- Groups were treated with spironolactone or cariporide.
- Cardiac fibrosis, hypertrophy, and NHE1 protein expression were assessed.
Main Results:
- Cariporide and spironolactone abolished DOCA/salt-induced perivascular collagen deposition.
- Cariporide completely suppressed interstitial collagen deposition, while spironolactone partially suppressed it.
- Cariporide completely inhibited DOCA/salt-induced cardiocyte hypertrophy and normalized increased NHE1 protein expression.
Conclusions:
- Cardiac NHE1 plays a significant role in DOCA/salt-induced cardiac fibrosis and hypertrophy.
- Cariporide effectively prevents DOCA/salt-induced cardiac injury, partly by inhibiting NHE1 activation.
- DOCA/salt-induced cardiac injury mediated by MRs involves partial activation of NHE1.
More Related Videos
Related Concept Videos
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Inotropic Agents

